10-Q: 10x Genomics Swings to Profit on Legal Wins, Acquires Scale Biosciences

10x Genomics reported a net income of $34.5 million in Q2 2025, driven by significant patent litigation settlements, and announced the acquisition of Scale Biosciences.

Summary

• Reported net income of $34.5 million for the three months ended June 30, 2025, a significant improvement from a net loss of $37.9 million in the prior year period.
• Achieved year-to-date net income of $0.2 million for the six months ended June 30, 2025, compared to a net loss of $97.8 million in the same period of 2024.
• Total revenue increased by 13% to $172.9 million in Q2 2025, primarily due to $27.8 million in license and royalty revenue from patent settlements.
• Products and services revenue decreased by 5% to $145.2 million in Q2 2025, with instrument revenue down 39% and Chromium consumables down 9%.
• Spatial consumables revenue grew by 24% to $36.4 million in Q2 2025, indicating strength in this product category.
• Gross margin improved to 72% in Q2 2025 from 68% in Q2 2024, largely influenced by the higher-margin license and royalty revenue.
• Operating expenses decreased by 35% to $95.0 million in Q2 2025, benefiting from a $40.7 million gain on settlement.
• Implemented a reduction in force on May 6, 2025, affecting approximately 8% of the global workforce, incurring $6.0 million in restructuring charges.
• Entered into a definitive agreement on August 7, 2025, to acquire Scale Biosciences, Inc. for $30 million in upfront cash and stock, plus contingent consideration.
• Settled patent litigation with Vizgen, Inc. in February 2025, receiving an upfront payment of $26.0 million and future royalties, contributing $9.2 million gain on settlement and $16.8 million license revenue.
• Settled patent litigation with Bruker Corporation in May 2025, securing $68.0 million in quarterly installment payments starting Q3 2025 and future royalties, contributing $40.7 million gain on settlement and $27.3 million license revenue.
• Cash and cash equivalents and marketable securities totaled $447.3 million as of June 30, 2025.

Sentiment

Score: 7

Explanation: The company achieved a significant turnaround to net income driven by successful patent settlements and cost reductions. While core product revenue saw declines, the strategic acquisition and strong cash position provide a positive outlook, though future revenue growth and sustained profitability remain key challenges.

Positives

• Achieved net income of $34.5 million in Q2 2025, a substantial turnaround from a $37.9 million net loss in Q2 2024.
• Total revenue increased by 13% year-over-year in Q2 2025, reaching $172.9 million, primarily driven by significant license and royalty revenue.
• Gross margin improved to 72% in Q2 2025 from 68% in Q2 2024, reflecting the impact of high-margin license revenue and lower royalties and warranty costs.
• Successful resolution of patent litigation with Vizgen, Inc. and Bruker Corporation, resulting in $44.8 million in license and royalty revenue and $49.9 million in gains on settlement year-to-date.
• Operating expenses decreased by 35% in Q2 2025, indicating effective cost reduction efforts and the benefit of settlement gains.
• Net cash provided by operating activities was $52.1 million for the six months ended June 30, 2025, a significant improvement from net cash used of $8.2 million in the prior year.
• Growth in Spatial consumables revenue by 24% in Q2 2025, indicating strength in a key product category.
• Acquisition of Scale Biosciences, Inc. could enhance the company's product portfolio and market position.
• The UPC issued a permanent injunction against Curio Bioscience, Inc. in Germany, France, and Sweden, protecting intellectual property.

Negatives

• Products and services revenue decreased by 5% in Q2 2025 and 4% year-to-date, indicating a decline in core product sales.
• Instrument revenue declined significantly by 39% in Q2 2025 and 41% year-to-date.
• Chromium consumables revenue decreased by 9% in Q2 2025 and 5% year-to-date.
• Incurred $6.0 million in restructuring charges in Q2 2025 due to a reduction in force impacting approximately 8% of the global workforce.
• Ongoing legal challenges with Parse Biosciences, Inc., with PTAB finding some asserted patents unpatentable, though the company is appealing.
• Anticipates a slight sequential decline in revenues (excluding license and royalty revenue) in Q3 2025.
• Expects to continue incurring operating losses in the near term.
• Accumulated deficit remains substantial at $1.5 billion as of June 30, 2025.

Risks

• Dependence on the successful commercialization and adoption of innovative life sciences technology products and solutions.
• Intense competition in the life sciences technology market, requiring continuous innovation and product development.
• Uncertainty and costs associated with intellectual property litigation, including the risk of adverse outcomes (e.g., PTAB findings against patents).
• Ability to integrate acquired businesses (e.g., Scale Biosciences, Inc.) and realize anticipated synergies and benefits.
• Fluctuations in gross margin due to non-recurring license and royalty revenue, changes in product mix, product prices, and manufacturing costs.
• Reliance on a limited number of key products (Chromium and Spatial instruments and consumables) for a significant portion of revenue.
• Potential for new risks and uncertainties to emerge that could impact financial and operating results.
• Ability to manage and reduce operating expenses effectively while continuing to invest in research and development.
• Exposure to foreign currency exchange rate fluctuations.
• Market conditions impacting the viability of financial institutions where cash and cash equivalents are held, potentially affecting access to uninsured funds.

Future Outlook

Management expects revenues, excluding the impact of license and royalty revenue, to slightly decline sequentially in the third quarter of 2025. Gross margin is anticipated to fluctuate through the remainder of 2025 due to the non-recurring benefit from license and royalty revenue, changes in product mix, product prices, and increased costs. Operating expenses are projected to trend lower in 2025 compared to the prior year, a result of cost reduction actions including the May 2025 reduction in force. The company expects to continue incurring operating losses in the near term and plans for aggregate capital expenditures of $15 million to $20 million over the next 12 months. Existing cash and cash equivalents and cash generated from sales are believed to be sufficient to meet anticipated cash needs for at least the next 12 months.

Management Comments

• "We expect our revenues, excluding the impact of license and royalty revenue, to slightly decline sequentially in the third quarter of 2025."
• "We expect our gross margin to fluctuate through the remainder of 2025 due to the non-recurring benefit in license and royalty revenue experienced in the first half of the year, as well as changes in product mix, changes in product prices and increased costs through the remainder of the year."
• "We expect our operating expenses to trend lower in 2025 versus prior year as a result of our actions to reduce operating costs including our May 2025 reduction in force that resulted in the termination of approximately 8% of our global workforce and additional planned reductions in non-headcount operating expenses."
• "We expect to continue to incur operating losses for the foreseeable future and to incur operating losses in the near term."
• "We believe that our existing cash and cash equivalents and cash generated from sales of our products will be sufficient to meet our anticipated cash needs for at least the next 12 months."

Industry Context

The life sciences technology industry, particularly in genomics and spatial biology, is highly innovative and competitive. 10x Genomics' focus on integrated research solutions with Chromium and Spatial instruments positions it within a growing market for advanced biological analysis tools. The decline in instrument and Chromium consumables revenue, despite growth in Spatial consumables, suggests a potential shift in market demand or increased competition in certain segments. The strategic acquisition of Scale Biosciences indicates a move to expand or strengthen its technology offerings, while aggressive patent enforcement through litigation and settlements highlights the importance of intellectual property in this high-value sector.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Legal Proceedings

• Settled worldwide patent litigation with Vizgen, Inc. in February 2025, granting Vizgen limited IP rights and securing an upfront payment of $26.0 million plus royalties.
• Settled all outstanding litigation with Bruker Corporation in May 2025, resulting in four quarterly installment payments totaling $68.0 million and future royalties.
• Ongoing patent infringement suit against Parse Biosciences, Inc. in the U.S. District Court for the District of Delaware, with some asserted patents found unpatentable by PTAB (appealed by the company) and a permanent injunction entered against Parse for certain ATAC-seq products.
• Ongoing patent infringement suit against Curio Bioscience, Inc. in the U.S. District Court for the District of Delaware, where most of Curio's counterclaims were dismissed, and trial on the company's affirmative case is scheduled for May 2026.
• A preliminary and then permanent injunction was issued by the Dusseldorf Local Division of the UPC against Curio Bioscience, Inc., prohibiting the sale of Seeker products in Germany, France, and Sweden due to patent infringement.
• PTAB denied institution of Curio's IPRs for multiple patents asserted by the company.

Stakeholder Impact

• Shareholders: Positive impact from significant legal settlements and the return to net income, potentially offset by declines in core product sales and ongoing litigation costs. The acquisition of Scale Biosciences could offer long-term growth potential.
• Employees: Negative impact due to the reduction in force affecting approximately 8% of the global workforce, leading to severance costs.
• Customers: Continued access to Chromium and Spatial products, with potential for expanded offerings through the Scale Biosciences acquisition.
• Creditors: Improved financial health with increased cash from operations and legal settlements, enhancing the company's ability to meet obligations.

Next Steps

• Substantially complete restructuring activities by the end of the third quarter of 2025.
• Begin receiving four quarterly installment payments from Bruker Corporation in the third quarter of 2025.
• Continue to analyze the provisions of the One Big Beautiful Bill Act (OBBBA) signed on July 4, 2025.
• Integrate Scale Biosciences, Inc. following the definitive agreement on August 7, 2025.
• Trial on the company's affirmative case against Curio Bioscience, Inc. is scheduled for May 2026.
• Continue to evaluate market conditions and potentially pursue additional sources of funding.

Key Dates

Recommendation

While 10x Genomics demonstrated a significant turnaround to net income in Q2 2025, primarily driven by substantial, non-recurring patent litigation settlements, core product and services revenue experienced declines. The strategic acquisition of Scale Biosciences and ongoing cost reduction efforts are positive, but the outlook for core revenue growth remains uncertain, with management anticipating a sequential decline in Q3. The company's strong cash position provides stability, but the accumulated deficit and the expectation of continued operating losses in the near term suggest a 'hold' position until there is clearer evidence of sustained organic revenue growth and profitability from its core business, beyond the one-time benefits of legal settlements.

Keywords

10x Genomics, TXG, Life Sciences Technology, Genomics, Spatial Biology, Single-Cell Analysis, Chromium Instruments, Visium CytAssist, Xenium Analyzer, Consumables, Patent Litigation, Vizgen Settlement, Bruker Settlement, Scale Biosciences Acquisition, Q2 2025 Earnings, SEC 10-Q, Biotechnology, Research Tools, Financial Results